Infant Phototherapy Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Infant Phototherapy Devices Market Trends and Insights

High Incidence of Neonatal Jaundice Sustains Device Demand

Neonatal jaundice affects 60% of term newborns and up to 80% of preterm infants globally during the first week of life. This clinical burden keeps phototherapy relevant across neonatal settings and provides the infant phototherapy devices market with a sustained treatment base. An estimated 10% of neonates require active phototherapy, which equates to 13-14 million infants each year based on WHO live-birth estimates. Severe neonatal jaundice among hospital admissions ranges from 0.73% to 3.34% across WHO regions, with the highest incidence reported in African and South-East Asian regions. The geographic pattern places greater weight on device affordability and dependable supply in these settings. It also supports demand for equipment that can perform reliably where clinical resources are constrained.

Rising Preterm and Low-Birth-Weight Deliveries Widen the Clinical Indication Base

Preterm and low-birth-weight infants have a higher risk of severe hyperbilirubinemia, expanding the number of newborns that may need phototherapy. This risk profile matters for the infant phototherapy devices market because preterm newborns often need longer treatment and stronger irradiance. They may also require double-surface treatment, increasing device use for each episode of care. A 2026 network meta-analysis found that double-surface phototherapy in preterm infants achieved higher total serum bilirubin reduction than single-surface treatment. This evidence supports the demand for systems that combine overhead light with a fiber-optic blanket. It also favors designs that can be used safely around medically fragile infants in incubators within the infant phototherapy devices market.

Expansion of Neonatal Intensive Care Capacity Unlocks Capital Equipment Procurement

NICU expansions in North America and Asia-Pacific support equipment procurement in the infant phototherapy devices market. Texas Children’s in Austin announced a USD 39 million NICU expansion in August 2026 that will increase its room count from 14 to 31^{[1]Texas Children’s Hospital, “Texas Children’s in Austin Announces NICU Expansion,” Texas Children’s Hospital, texaschildrens.org}. The project is expected to serve up to 300 additional patient episodes annually when completed in fall 2027. New beds require phototherapy equipment, irradiance meters, and bilirubin monitoring tools as part of neonatal care operations. Capacity growth, therefore, creates a direct connection between facility investment and device purchasing. The effect is strongest where hospitals are upgrading both physical space and clinical workflows at the same time.

LED Technology Displacement Reshapes Device Economics

The replacement of fluorescent and quartz-halogen systems with LED units is changing purchasing decisions in the infant phototherapy devices market. A 2025 study found that LED phototherapy produced bilirubin reduction comparable with compact fluorescent lamp systems and was associated with fewer adverse effects. The same study reported peak bilirubin reductions of 28-43% within 48-96 hours for modern LED units. Blue LED systems operating at 450-475 nm align with bilirubin’s peak absorption wavelength under American Academy of Pediatrics guidance. LED lamps also have operating lives exceeding 10,000 hours, compared with 500-1,000 hours for conventional fluorescent tubes. These operating characteristics support replacement demand across the infant phototherapy devices market, although lower-cost LED retrofits can place pressure on the prices of fully integrated systems.

High Upfront Cost of Advanced Devices Constrains Emerging-Market Procurement

Advanced LED systems can strain public procurement budgets in emerging markets. Double-surface units and systems with integrated monitoring have higher acquisition requirements than basic overhead equipment. Hospitals in South Asia and sub-Saharan Africa may continue using single fluorescent units when capital budgets are limited. This can reduce irradiance performance and leave clinical needs less fully addressed. Total ownership costs also include irradiance measurement tools, eye protection supplies, and replacement lamps for non-LED equipment. Manufacturers in the infant phototherapy devices market are responding with modular and battery-compatible systems, but tender-based buying processes can extend sales cycles and limit margins.

Monitoring Requirements Create a Dual Infrastructure Burden

Effective phototherapy depends on the device as well as reliable serum bilirubin measurement and irradiance verification. The American Academy of Pediatrics’ 2024 guidance bases treatment adjustments on total serum bilirubin measurement. IEC 60601-2-50 also specifies irradiance requirements at the patient surface. These requirements create operational burdens where testing tools and trained staff are not consistently available. Inconsistent measurement can lead to therapy ending too early or continuing longer than necessary. The infant phototherapy devices market must therefore accommodate facilities that need dependable hardware while also building their monitoring processes.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Light Source: LED Efficiency Reshapes Device Economics

Light-emitting diodes held 48.31% of the light-source segment in 2025 and are forecast to expand at a 5.65% CAGR through 2031. LED systems work within the 450-475 nm range that aligns with bilirubin absorption requirements. Modern units achieved bilirubin reductions of 28-43% within 48-96 hours in a 2025 study. They also generated less heat and fewer adverse events than fluorescent alternatives in the reported comparison. The infant phototherapy devices industry is placing more value on energy efficiency, lamp durability, and consistent light output.

Fluorescent lamps retained an installed base in lower-resource settings where the initial price remains important. Their shorter operating life creates recurring maintenance requirements compared with LED equipment. Quartz-halogen lamps are declining because high heat can increase insensible water loss in newborns. Gas discharge tubes retain a narrower role in specialized combined systems. IEC 62471 safety requirements and clinical irradiance guidance increasingly support LED-centered designs in the infant phototherapy devices market.

By Care Setting: NICUs Anchor Volume While Homecare Drives the Growth Curve

Hospitals and NICUs represented 75.24% of the infant phototherapy devices market size by care setting in 2025. Institutional care can provide irradiance monitoring, serum bilirubin testing, and continuous nursing oversight. These capabilities remain necessary for newborns with neurotoxicity risk factors. The American Academy of Pediatrics identifies preterm infants below 38 weeks of gestation and newborns with hemolytic disease as patients requiring careful management. Ongoing NICU projects in North America and Asia-Pacific will continue to support institutional procurement through 2031.

Homecare settings are forecast to grow at a 5.22% CAGR from 2026 to 2031. Structured programs allow suitable low-risk term newborns to receive treatment outside an inpatient bed. A 2026 systematic review found comparable total serum bilirubin reduction for selected home and in-hospital patients. It also reported a 3.5% readmission rate and 70% lower cost for home phototherapy in structured hospital-at-home programs. Singapore’s KKH@Home program recruited 134 patients from April through December 2024 and saved 200 inpatient bed-days, reinforcing the role of compact fiber-optic, portable, and wearable equipment in the infant phototherapy devices market^{[2]KKH@Home, “KKH@Home Home Phototherapy Program,” CHI Innovate 2025, chiinnovate2025.klobbi.com}.

By Treatment Intensity: Standard Protocols Hold Share, Combination Systems Lead Growth

Standard-intensity phototherapy held the largest treatment-intensity share at 44.14% in 2025. It remains the first treatment option for physiological and mild neonatal hyperbilirubinemia in term infants. Major clinical protocols use standard overhead phototherapy before escalation when clinical needs require it. Single-surface LED units are widely suited to this established care pathway. This broad clinical role gives standard-intensity equipment a stable position in the infant phototherapy devices market.

Combined overhead and fiber-optic phototherapy is projected to grow at a 5.42% CAGR from 2026 to 2031. This configuration exposes the dorsal surface through overhead irradiance and the ventral surface through an under-blanket device. It can increase the treated body surface area without repeatedly repositioning the infant. A 2026 analysis confirmed higher total serum bilirubin reduction from double-surface treatment. Intensive devices for Level III and IV NICUs must meet the American Academy of Pediatrics threshold of 30 µW/cm²/nm, separating premium systems from basic units.

By Clinical Use: Physiological Jaundice Anchors Volume, Preterm Cases Fuel Innovation

Physiological jaundice accounted for 49.54% of the clinical-use segment in 2025. It is the most common cause of neonatal hyperbilirubinemia in the first days of life. This clinical use supports continuing demand for standard treatment equipment. Breast milk jaundice affects 15% of exclusively breastfed infants beyond 3 weeks of life, but it generally involves lower bilirubin elevations. The infant phototherapy devices industry continues to rely on physiological jaundice as its largest routine treatment need.

Jaundice in preterm infants is forecast to grow at a 5.12% CAGR from 2026 to 2031. Preterm newborns are treated at lower bilirubin thresholds and may need higher irradiance levels. They also more frequently need combined-surface delivery than term newborns. These care requirements increase device use for each treated infant. A 2025 pilot study of the Jauni wearable phototherapy romper involved 10 neonates and reported a total serum bilirubin reduction rate of 1.6 µmol/L/h while enabling parental holding.

Geography Analysis

North America held 36.61% of the regional share in 2025. The region benefits from extensive NICU infrastructure and strong procurement of higher-specification equipment. Texas Children’s announced its USD 39 million Austin expansion in August 2026, with room capacity set to rise from 14 to 31. The project is expected to serve up to 300 additional patient episodes annually when completed in fall 2027. These expansions create continuing purchase needs for phototherapy systems and related monitoring equipment in the infant phototherapy devices market.

Europe held the second-largest geographic share in 2025. Germany, the United Kingdom, and France account for a significant portion of regional revenue. German practice uses age-stratified bilirubin thresholds, including a 20 mg/dL trigger for healthy term infants aged 72 hours or more. German neonatal units have adopted LED systems at a high rate because of strict photobiological safety expectations. Universitätsmedizin Halle tested a phototherapy sleeping-bag system that supports breastfeeding and skin-to-skin contact during treatment.

Asia-Pacific is the fastest-growing regional area at a 5.65% CAGR from 2026 to 2031. China’s NICU capacity expanded by 7-8% annually from 2020 to 2025 under Healthy China 2030, supporting domestic equipment demand. The installed base of phototherapy machines in China is projected to exceed 200,000 units by 2030. India’s increasing institutional deliveries and neonatal screening requirements also support regional demand in the infant phototherapy devices market.